Makers Laboratories Ltd

Makers Laboratories Ltd

192.00
INR
0.00
(0.00%)
18.99EPS
25.10P/E
860.57MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
133.42
126.67
119.83
113.43
109.17
90.98
100.29
138.87
246.96
167.68
175.86
203.42
236.47
252.19
Basic EPS, GAAP
1.16
4.59
4.5
7.22
5.97
4.78
-0.24
-0.67
9.71
-7.9
-10.62
12.7
3.99
5.81
Free Cash Flow per Basic Share
-2.63
-1.36
2.87
-6.52
-3.68
-6.9
-8.51
- -
16.8
-35.8
-9.8
-13.59
17.93
- -
Dividend per Share
- -
- -
1.15
1.15
1.15
1.12
1.15
- -
1.23
1.05
1.07
- -
- -
- -
Book Value per Share
44.69
48.05
59.65
66.47
71.85
81.37
87.07
105.62
121.17
117.28
106.85
119.49
123.59
- -
Tangible Book Value per Share
44.5
47.92
59.57
66.44
71.84
81.37
86.93
104.98
120.71
116.06
104.94
117.76
121.92
- -
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
5
6
6
6
6
6
Sales/Revenue/Turnover
684
649
614
581
559
466
514
683
1,266
1,008
1,038
1,200
1,395
1,484
Operating Margin (%)
1.56
4.68
6.03
7.53
5.81
2.55
2.16
6.6
11.92
-0.72
-3.12
3.5
7.5
9.54
Depreciation Expense
10
15
13
11
16
15
20
46
40
42
45
48
45
45
Net Income, GAAP
6
24
23
37
31
24
-1
-3
50
-48
-63
75
24
34
Effective Tax Rate (%)
49.84
30.82
34.18
30.67
27.83
18.81
149.72
50.14
25.31
- -
- -
18.67
29.5
27.78
Profit Margin (%)
0.87
3.62
3.76
6.36
5.46
5.25
-0.24
-0.48
3.93
-4.71
-6.04
6.24
1.69
2.3
Working Capital
104
120
104
99
121
115
44
279
299
357
326
471
529
- -
LT Debt
- -
- -
- -
- -
- -
60
80
77
46
61
107
34
20
- -
Total Equity
229
246
306
341
368
417
446
866
981
1,097
1,043
1,152
1,225
- -
Return on Invested Capital (%)
2.08
9.69
7.56
10.64
5.85
1.97
-0.97
2.17
9.95
- -
- -
9
5.83
- -
Return on Capital (%)
3.13
10.37
8.96
11.74
9.01
6.16
-0.9
-1.43
-0.46
- -
- -
4.19
-2.1
- -
Return on Common Equity (%)
2.63
9.9
8.36
11.45
8.62
6.24
-0.29
-0.67
8.76
-7.38
-9.47
11.22
3.28
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
41
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
10
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
697
798
861

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
869
- -
Cash, Cash Equivalents & STI
- -
118
- -
Accounts Receivable, Net
- -
199
- -
Inventories
- -
449
- -
Total Current Liabilities
- -
340
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
41
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.08%
7.39%
6.32%
Free Cash Flow
- -
- -
-231.9%
Net Income, GAAP
-198%
-412.81%
-68.61%
Sales/Revenue/Turnover
11.71%
19.97%
16.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
296
296
277
339
1,200
2026
350
342
357
358
1,395
2027
428
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-1.67
14.94
-0.5
-0.08
12.7
2026
0.74
-0.2
1.59
1.85
3.99
2027
2.55
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Saahil Umesh Parikh
Full Time Employees
114
Sector
Health technology
Industry
Pharmaceuticals: major
Address
54-D, Kandivli Industrial Estate Mumbai MA India 400067
IPO Date
Jul 13, 1993
Business
Makers Laboratories Limited is an Indian pharmaceutical company specializing in the manufacturing and marketing of pharmaceutical formulations and drug intermediates. Its product portfolio includes tablets, capsules, liquids, injectables, creams, and ointments, with key brands such as Duramol (Paracetamol), Artemak-AB (α-β Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (cough remedies), and Exylin (Amoxycillin range). The company operates primarily in India and focuses on branded generics across a wide range of general health therapeutic segments. Founded in 1984 and headquartered in Mumbai, Maharashtra, Makers Laboratories maintains a strong supply chain with significant operations in formulation drugs and drug intermediates. In recent years, Makers Laboratories has undergone significant strategic expansion through the acquisition of a controlling stake in Resonance Specialties Limited in 2020, facilitating its entry into specialty chemicals, active pharmaceutical ingredients (API), and drug intermediates businesses that complement its generic formulations. It has also upgraded and modernized its manufacturing plants, including capacity enhancement and the launch of new ophthalmic products at the Naroda facility in Ahmedabad. The company has continued to report steady growth in sales and operational efficiency, supported by a robust distribution network across India and a strong vendor/supplier base. Makers Laboratories extends its pharmaceutical offerings through segments such as analgesics, anti-infectives, anti-malarials, anti-inflammatory drugs, and respiratory care. Its manufacturing facilities cover solid dosage forms, liquid formulations, injectables, and dermatological products. The company also offers supplementary products like nutritional malt preparations. Recent operational improvements include enhancements in the liquid injectable manufacturing unit and introduction of new product lines aimed at broadening the therapeutic coverage and market presence. Overall, Makers Laboratories Limited is positioned as a comprehensive pharmaceutical manufacturer with diversified product categories spanning branded generics, APIs, and specialty chemicals, supported by recent acquisitions and facility upgrades that underline its strategic intent to strengthen its footprint in the Indian pharmaceutical industry and related chemical sectors.